ERCC2 and neoplasm: XPD has effects on progression of a broad palette of tumor types when mutated or altered—increased or decreased—in expression, and variants in ERCC2 have been associated with altered drug response, especially platinum-based therapies (Du et al., 2014; Fu et al., 2017; Tan et al., 2017; Pajuelo-Lozano et al., 2018; Liu et al., 2019).